Sanofi Reports 4Q18 Orthobiologic Revenue of €81MM, -5.8% vs. 4Q17

Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $93.1MM in 4Q18, -5.8% vs. 4Q17. For full year 2018, sales of those products totaled $359.6MM, -19.1% vs. 2017. Sales in the U.S., the primary market for Synvisc, declined 9.8%. This was somewhat offset by performance in emerging markets, where sales...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us